20 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 8 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 5 | 7 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 2 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $294.95, a high estimate of $364.00, and a low estimate of $215.00. This current average represents a 4.71% decrease from the previous average price target of $309.54.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in-depth analysis of recent analyst actions...
Login or create a forever free account to read this news
Sign up/Log in